Skip to main content

Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?

Current Treatment Options in Oncology volume 13, pages 478–490 (2012)Cite this article

Opinion statement

The standard of care for the treatment of patients with advanced NSCLC includes 4-6 cycles of platinum-doublet chemotherapy with or without bevacizumab, with modest improvements in survival. To improve upon outcomes, recent studies have investigated the role of maintenance therapy after first-line chemotherapy. This concept can be divided into continuation and switch maintenance. The majority of studies have shown significant improvements in progression-free survival (PFS) with the addition of maintenance, but the improved PFS has not always resulted in an improvement of overall survival (OS). Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. Whether maintenance pemetrexed improves OS compared with treatment with pemetrexed at progression is unknown. Recent trials suggest that maintenance therapy benefits both patients with initial response and stable disease after chemotherapy. There is insufficient evidence to support recommending the combination of pemetrexed and bevacizumab over maintenance pemetrexed alone as a switch maintenance approach, although the combination seems to be more effective than bevacizumab alone. The ongoing ECOG 5508 trial is examining this question. For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. Switch maintenance with docetaxel or continuation maintenance with gemcitabine confers improvements in PFS regardless of histology but has failed to show improvements in OS. For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. Overall, maintenance therapy may benefit patients with good performance status who complete four cycles of induction chemotherapy with manageable toxicity, but there is insufficient evidence to make this a blanket recommendation for everyone. Maintenance should remain an individual decision between patients and the treating oncologist.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 1995. 311(7010):899–909.

  2. Sandler A, et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542–50.

    PubMed  Article  CAS  Google Scholar 

  3. Scagliotti GV, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2008;26(21):3543–51.

    PubMed  Article  CAS  Google Scholar 

  4. Socinski MA, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1335–43.

    PubMed  Article  CAS  Google Scholar 

  5. von Plessen C, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006;95(8):966–73.

    Article  Google Scholar 

  6. Belani CP, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21(15):2933–9.

    PubMed  Article  CAS  Google Scholar 

  7. Brodowicz T, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52(2):155–63.

    PubMed  Article  Google Scholar 

  8. Perol M, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. ASCO Meet Abstr. 2010;28(15_suppl):7507.

    Google Scholar 

  9. Belani CP, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2010;28(15_suppl):7506.

    Google Scholar 

  10. Paz-Ares L, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–55.

    PubMed  Article  CAS  Google Scholar 

  11. Paz-Ares L, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2012;30(15_suppl):LBA7507.

    Google Scholar 

  12. Barlesi F, et al. AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). Eur J Cancer. 2011;47(Supplement 2(0)):16.

    Article  Google Scholar 

  13. Barlesi F, et al. AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). Eur J Cancer. 2011;47:16.

    Article  Google Scholar 

  14. Fidias PM, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591–8.

    PubMed  Article  CAS  Google Scholar 

  15. Ciuleanu T, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–40.

    PubMed  Article  CAS  Google Scholar 

  16. Belani CP, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13(3):292–9.

    PubMed  Article  CAS  Google Scholar 

  17. Reck M, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.

    PubMed  Article  CAS  Google Scholar 

  18. Miller VA, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2009;27(18S):LBA8002.

    Google Scholar 

  19. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.

    PubMed  Article  CAS  Google Scholar 

  20. Bezjak A, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24(24):3831–7.

    PubMed  Article  CAS  Google Scholar 

  21. Cappuzzo F, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9.

    PubMed  Article  CAS  Google Scholar 

  22. Brugger W, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(31):4113–20.

    PubMed  Article  CAS  Google Scholar 

  23. Kabbinavar FF, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2010;28(15_suppl):7526.

    Google Scholar 

  24. Mok T, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. ASCO Meet Abstr. 2012;30(15_suppl):7519.

    Google Scholar 

  25. Takeda K, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010;28(5):753–60.

    PubMed  Article  CAS  Google Scholar 

  26. Gaafar RM, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011;47(15):2331–40.

    PubMed  Article  CAS  Google Scholar 

  27. Zhang L, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13(5):466–75.

    PubMed  Article  CAS  Google Scholar 

  28. Matter-Walstra K, et al. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health. 2012;15(1):65–71.

    PubMed  Article  Google Scholar 

  29. Dickson R, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. PharmacoEconomics. 2011;29(12):1051–62.

    PubMed  Article  Google Scholar 

Download references

Disclosures

N. Hashemi-Sadraei: none; N.A. Pennell: Consultancy for Boehringer Ingelheim, Teva, and Oncogenex.

Author information

Affiliations

  1. Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, R35, Cleveland, OH, 44195, USA

    Nooshin Hashemi-Sadraei MD & Nathan A. Pennell MD, PhD

Authors
  1. Nooshin Hashemi-Sadraei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan A. Pennell MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nooshin Hashemi-Sadraei MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hashemi-Sadraei, N., Pennell, N.A. Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?. Curr. Treat. Options in Oncol. 13, 478–490 (2012). https://doi.org/10.1007/s11864-012-0209-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0209-1

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Maintenance therapy
  • Chemotherapy
  • Pemetrexed
  • Erlotinib
  • Gefitinib
  • Bevacizumab